EMERYVILLE -
The goal of the
PhenomeX's fluorescent SpotLight reagents, which are non-destructive and certified as animal- component free, allow early productivity and product quality screens to be run in parallel across thousands of clonal populations.
SpotLight Human Fc reagent binds to the Fc region of human antibodies
SpotLight Human Kappa reagent binds to the kappa light chain of human antibodies
Soon-to-be released SpotLight Human Lambda reagent binds to the lambda light chain of human antibodies
As demonstrated by GSK, these reagents can be used individually for screening of monospecific antibodies or in combination to screen bispecific lambda-kappa antibodies.
Dr.
About
PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding PhenomeX or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. PhenomeX undertakes no obligation to update or revise any forward-looking statements.
Contact:
Tel: +1 (510) 858-2855
Email: IR@PHENOMEX.COM
(C) 2023 Electronic News Publishing, source